We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > DAPA-HF

News List

Forxiga successful in DAPA-HF heart failure trial pharmatimes
March 31, 2020
New data from a sub-analysis of AstraZeneca’s Phase III DAPA-HF trial has shown that Forxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo.
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure worldpharmanews
August 21, 2019
AstraZeneca announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and ...